Research & Development: Page 3
-
magicmine, iStock / Getty Images Plus via Getty Images
How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology
After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma giants are even more ambitious for the next wave of biologic medicines.
By Michael Gibney • March 27, 2025 -
Permission granted by Novavax
ProfileThe industry heavyweight behind Novavax’s push to bounce back
As it returns from the brink, the vaccine developer has brought in Dr. Ruxandra Draghia-Akli — and her industry and public health chops — to lead R&D.
By Alexandra Pecci • March 25, 2025 -
Explore the Trendline➔
Stock via Getty Images
TrendlineBig Pharma Business Strategies
Large pharmas are consistently tasked with the goal of growth. But in recent years, the upward trajectory has been littered with new hurdles.
By PharmaVoice staff -
Jacob Bell/PharmaVoice
Biogen plots new global headquarters in Kendall Square
The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development project spearheaded by MIT.
By Jacob Bell • March 25, 2025 -
Stock via Getty Images
Biotechs emerging from stealth take aim at pharma’s prime targets
The companies are striving to bring fresh innovations to cancer care, pain management and the weight loss space.
By Kelly Bilodeau • March 24, 2025 -
Stock via Getty Images
How pharma could feel the pain of a recession
Pharma has long been considered “recession proof,” but an economic downturn could still hurt the industry in numerous ways.
By Meagan Parrish • March 21, 2025 -
Courtesy of Sarepta
Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades
The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also enduring tragic risk.
By Michael Gibney • March 20, 2025 -
Stock via Getty Images
The key factors shaping China’s biopharma boom
Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles could stymie dealmaking.
By Alexandra Pecci • March 19, 2025 -
Permission granted by Diakanos
Q&AHow non-traditional investors fuel up-and-coming biotechs when VC funding dries up
Smaller biotechs are finding creative ways to fund R&D at a time when the traditional financing channels have become more constrictive.
By Michael Gibney • March 18, 2025 -
Stock via Getty Images
Drug developers ‘haven’t even scratched the surface’ of what radiopharma can do
Even with Big Pharmas pouring billions into the space, the potential of radiopharmaceuticals remains largely untapped.
By Kelly Bilodeau • March 17, 2025 -
Permission granted by Roche
Q&ARoche’s obesity deal with Zealand Pharma tees up rival for GLP-1s
The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.
By Amy Baxter • March 17, 2025 -
Stock via Getty Images
Takeda’s $770M deal deepens Big Pharma’s omics push
The pharma giant announced a new partnership with BridGene Biosciences that will use its IMTAC platform for drug discovery.
By Alexandra Pecci • March 13, 2025 -
Stock via Getty Images
The first new type of drug for Tourette syndrome in over 50 years is close to the FDA’s doorstep
Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.
By Amy Baxter • March 11, 2025 -
Permission granted by Biogen
What’s driving pharma’s layoffs in 2025
Familiar foes in the industry have claimed a slew of jobs in recent months.
By Meagan Parrish • March 10, 2025 -
Kevin C. Cox via Getty Images
The top 3 impacts of Trump’s health data purge
Interrupted access to health-related data has already led to worse outcomes and could undermine faith in the U.S. healthcare system, experts say.
By Michael Brady • March 6, 2025 -
Mario Tama via Getty Images
With patent losses on the horizon, Amgen refocuses its business strategy
The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.”
By Alexandra Pecci • March 5, 2025 -
Courtesy of AbbVie
AbbVie gets into obesity with $350M deal for once-weekly shot
A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.
By Jonathan Gardner • March 5, 2025 -
Stock via Getty Images
Americans want to participate in clinical trials — so why don’t they?
A recent study revealed the key barriers to enrollment and how pharma can help turn the tide.
By Kelly Bilodeau • March 4, 2025 -
Permission granted by Voyager Therapeutics
New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach
Voyager Therapeutics’ progress with drug candidates targeting tau marks a step in how the industry is walking multiple paths toward new therapeutic options.
By Michael Gibney • March 4, 2025 -
Permission granted by Teva
Teva targets schizophrenia to build on innovative medicines growth
The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.
By Meagan Parrish • Feb. 28, 2025 -
Permission granted by Recursion
Q&AAI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration
Recursion CFO Ben Taylor discusses the state of AI M&A and what companies should look for as the industry moves to new data technologies and systems.
By Michael Gibney • Feb. 27, 2025 -
Getty Images via Getty Images
Cancer vaccines have stumbled, but the approach is gaining new steam
The number of candidates in development has nearly doubled over the past 15 years.
By Kelly Bilodeau • Feb. 26, 2025 -
Stock via Getty Images
Its CEO died. The company scrapped a promising program. Now, for their 2nd act.
Terns Pharmaceuticals sees blockbuster promise for two potential best-in-class molecules in obesity and oncology.
By Alexandra Pecci • Feb. 25, 2025 -
Getty Images via Getty Images
Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide
Orphan drug development has long been incentivized by government policy. But as the financial math shifts, so do the risks of bringing rare disease drugs to market.
By Michael Gibney • Feb. 25, 2025 -
Stock via Getty Images
Q&AMerck, Lilly launch manufacturing R&D consortium to help ‘bolster’ U.S. production
The Young Institute Pharmaceutical Manufacturing Consortium will research and develop new production technologies.
By Alexandra Pecci • Feb. 19, 2025 -
Stock via Getty Images
Biotech SpotlightCRISPR’s cardio catch-all drives a biotech’s broad potential
Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.
By Kelly Bilodeau • Feb. 18, 2025
Previous
